Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer

Y. Ohe, D. Zhao, N. Saijo, E. R. Podack

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Bovine papillomavirus type 1 (BPV-1)-derived vectors may be useful for gene therapy because of their episomal maintenance at intermediate to high copy number and stable, high-level expression of gene products. To increase the safety of BPV-1 for human trials, the transforming early genes E5, E6, and E7 were deleted and a new vector, B45-Neo, was established and its transforming potential, episomal maintenance, and cDNA expression determined. Deletion of E5, E6, and E7, caused a decrease of the copy number to 80 in 3T3 fibroblasts when B45-Neo was compared to the parent vector that supported more than 1,000 copies per cell. No significant difference in the copy number, which ranged between 13 and 30 per cell, was detected in other cell lines of murine or human origin. The episomal maintenance of B45 and its ability to express cDNA was retained. B45-Neo, in contrast to BMG-Neo, however, was unable to transform NIH-3T3 and C1271 cells in soft agar colony assays. Unlike BMG-Neo, B45-Neo did not cause morphological changes in 3T3 and C1271 cells characteristic for transformation. It is concluded that B45-Neo is an efficient expression vector without detectable transforming activity and may be useful and safe for human gene therapy trials.

Original languageEnglish
Pages (from-to)325-333
Number of pages9
JournalHuman Gene Therapy
Volume6
Issue number3
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Bovine papillomavirus 1
Maintenance
Genetic Therapy
Complementary DNA
Genes
3T3 Cells
NIH 3T3 Cells
Oncogenes
Agar
Fibroblasts
Safety
Gene Expression
Cell Line

ASJC Scopus subject areas

  • Genetics

Cite this

Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. / Ohe, Y.; Zhao, D.; Saijo, N.; Podack, E. R.

In: Human Gene Therapy, Vol. 6, No. 3, 01.01.1995, p. 325-333.

Research output: Contribution to journalArticle

@article{b3c0932150e34e5389a3a0e8e389ab29,
title = "Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer",
abstract = "Bovine papillomavirus type 1 (BPV-1)-derived vectors may be useful for gene therapy because of their episomal maintenance at intermediate to high copy number and stable, high-level expression of gene products. To increase the safety of BPV-1 for human trials, the transforming early genes E5, E6, and E7 were deleted and a new vector, B45-Neo, was established and its transforming potential, episomal maintenance, and cDNA expression determined. Deletion of E5, E6, and E7, caused a decrease of the copy number to 80 in 3T3 fibroblasts when B45-Neo was compared to the parent vector that supported more than 1,000 copies per cell. No significant difference in the copy number, which ranged between 13 and 30 per cell, was detected in other cell lines of murine or human origin. The episomal maintenance of B45 and its ability to express cDNA was retained. B45-Neo, in contrast to BMG-Neo, however, was unable to transform NIH-3T3 and C1271 cells in soft agar colony assays. Unlike BMG-Neo, B45-Neo did not cause morphological changes in 3T3 and C1271 cells characteristic for transformation. It is concluded that B45-Neo is an efficient expression vector without detectable transforming activity and may be useful and safe for human gene therapy trials.",
author = "Y. Ohe and D. Zhao and N. Saijo and Podack, {E. R.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "325--333",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer

AU - Ohe, Y.

AU - Zhao, D.

AU - Saijo, N.

AU - Podack, E. R.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Bovine papillomavirus type 1 (BPV-1)-derived vectors may be useful for gene therapy because of their episomal maintenance at intermediate to high copy number and stable, high-level expression of gene products. To increase the safety of BPV-1 for human trials, the transforming early genes E5, E6, and E7 were deleted and a new vector, B45-Neo, was established and its transforming potential, episomal maintenance, and cDNA expression determined. Deletion of E5, E6, and E7, caused a decrease of the copy number to 80 in 3T3 fibroblasts when B45-Neo was compared to the parent vector that supported more than 1,000 copies per cell. No significant difference in the copy number, which ranged between 13 and 30 per cell, was detected in other cell lines of murine or human origin. The episomal maintenance of B45 and its ability to express cDNA was retained. B45-Neo, in contrast to BMG-Neo, however, was unable to transform NIH-3T3 and C1271 cells in soft agar colony assays. Unlike BMG-Neo, B45-Neo did not cause morphological changes in 3T3 and C1271 cells characteristic for transformation. It is concluded that B45-Neo is an efficient expression vector without detectable transforming activity and may be useful and safe for human gene therapy trials.

AB - Bovine papillomavirus type 1 (BPV-1)-derived vectors may be useful for gene therapy because of their episomal maintenance at intermediate to high copy number and stable, high-level expression of gene products. To increase the safety of BPV-1 for human trials, the transforming early genes E5, E6, and E7 were deleted and a new vector, B45-Neo, was established and its transforming potential, episomal maintenance, and cDNA expression determined. Deletion of E5, E6, and E7, caused a decrease of the copy number to 80 in 3T3 fibroblasts when B45-Neo was compared to the parent vector that supported more than 1,000 copies per cell. No significant difference in the copy number, which ranged between 13 and 30 per cell, was detected in other cell lines of murine or human origin. The episomal maintenance of B45 and its ability to express cDNA was retained. B45-Neo, in contrast to BMG-Neo, however, was unable to transform NIH-3T3 and C1271 cells in soft agar colony assays. Unlike BMG-Neo, B45-Neo did not cause morphological changes in 3T3 and C1271 cells characteristic for transformation. It is concluded that B45-Neo is an efficient expression vector without detectable transforming activity and may be useful and safe for human gene therapy trials.

UR - http://www.scopus.com/inward/record.url?scp=0028991823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028991823&partnerID=8YFLogxK

M3 - Article

C2 - 7779916

AN - SCOPUS:0028991823

VL - 6

SP - 325

EP - 333

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -